Structure-Function and Inhibition of Rnr1
Rnr1 的结构-功能和抑制
基本信息
- 批准号:7909255
- 负责人:
- 金额:$ 40.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-01 至 2011-07-31
- 项目状态:已结题
- 来源:
- 关键词:Antineoplastic AgentsAntiviral AgentsBindingBinding SitesBiological AssayC-terminalCancer CenterCatalytic DomainCellsChemicalsClofarabineComplexCrystallizationDigestionDiphosphatesDiseaseDrug DesignEnzymesEquilibriumEukaryotaFluorescenceFred Hutchinson Cancer Research CenterHumanLinkMalignant NeoplasmsMapsMass Spectrum AnalysisMismatch RepairMusMutationNucleotidesPeptidesProductionProliferatingProteinsProteolysisResearch InstituteRibonucleotide ReductaseRoentgen RaysRoleSaccharomyces cerevisiaeSiteSite-Directed MutagenesisSpecificityStructureSubstrate SpecificitySuppressor MutationsSurfaceTechniquesTestingTherapeutic InterventionViralWorkYeast Model SystemYeastsbasechemotherapeutic agentcrosslinkdeoxyguanosine triphosphatedesigngemcitabineinhibitor/antagonistknowledge basemutantnovelpeptidomimeticsprotein complexresearch studysmall moleculethree dimensional structure
项目摘要
DESCRIPTION (provided by applicant): Ribonucleotide Reductase, (RNR) is a multi-subunit enzyme that catalyzes the rate-limiting step of de novo precursor DMA synthesis by converting nucleotide diphosphates to deoxynucleotide diphosphates. Crucial for rapidly proliferating cells, RNR is a target for anti-cancer and anti-viral therapy. Recently, we solved the first X -ray structures of eukaryotic ribonucleotide reductase 1 from Saccharomyces cerevisiae. The twelve structures solved reveal two new domains, the structural basis for substrate selection in eukaryotes and the mode of binding of the anti-cancer drug Gemcitabine and ribonucleotide reductase based peptides; the latter complex provides a framework for designing anti-cancer drugs that disrupt the enzyme's multi-subunit assembly. We have expressed and purified the human Rnr1 for crystallization. Until the mammalian Rnr1 structure is solved, the yeast structures provide an invaluable starting point for designing inhibitors that target Rnr1. We will solve the X-ray structures of Rnr1 complexed with inhibitors that target the effector sites (Eg. Clofarabine) and catalytic site (3NUDP) as well as bifunctional molecules that target both effector and catalytic sites (dGTP-ADP linked covalently), and peptidomimetics that disrupt RNR assembly. These structures will provide a starting point for knowledge based drug design. As a proof of principle we have shown that a mouse Rnr2 based inhibitor binds yeast Rnr1. The compounds have been provided by our collaborators Dr. Barry Cooperman (UPENN), Dr. Vasha Ghandi (MD Anderson), and Dr. Willam Parker at the Southern Research Institute. We will also study how SmM binds Rnr1 using cross-linking, limited proteolysis, surface mapping in tandem with mass spectrometry. The structures of intact Sml1-Rnr1 and Rnr1-Sml1peptide complexes will be determined. We will use site-directed mutagenesis to confirm the MS results on the Sml1 binding site, identify the function of the newly identified insert domains and the role of crucial residues identified by our structures that confer substrate specificity. Finally, we will investigate the structural basis of the synthetically lethal mismatch repair mutants identified by Dr. Julian Simon at the Fred Hutchninson Cancer Center. The work proposed will further our understanding on how the vital enzyme ribonucleotide reductase is regulated and the structure based design of inhibitors against it will be important for the therapeutic intervention of proliferative diseases such as cancer.
描述(由申请人提供):核糖核苷酸还原酶(RNR)是一种多亚基酶,通过将核苷酸二磷酸转化为脱氧核苷酸二磷酸来催化从头合成前体DMA的限速步骤。RNR对快速增殖的细胞至关重要,是抗癌和抗病毒治疗的靶标。最近,我们从酿酒酵母中首次获得了真核生物核糖核苷酸还原酶1的X射线结构。这12个结构揭示了两个新的结构域,即真核生物底物选择的结构基础和抗癌药物吉西他滨与核糖核苷酸还原酶基肽的结合模式;后一种复合物为设计破坏酶的多亚基组装的抗癌药物提供了框架。我们表达并纯化了人Rnr1用于结晶。在哺乳动物Rnr1结构被解决之前,酵母结构为设计靶向Rnr1的抑制剂提供了宝贵的起点。我们将解决Rnr1与靶向效应位点的抑制剂络合的x射线结构(例如;氯法拉滨)和催化位点(3NUDP),以及靶向效应位点和催化位点的双功能分子(dGTP-ADP共价连接),以及破坏RNR组装的肽拟物。这些结构将为基于知识的药物设计提供一个起点。作为一个原理证明,我们已经证明了一个基于小鼠Rnr2的抑制剂可以结合酵母Rnr1。这些化合物由我们的合作者Barry Cooperman博士(UPENN), Vasha Ghandi博士(MD Anderson)和william Parker博士在南方研究所提供。我们还将研究SmM如何结合Rnr1使用交联,有限的蛋白水解,表面制图串联质谱。完整的Sml1-Rnr1和rnr1 - sml1肽复合物的结构将被确定。我们将使用位点导向突变来确认Sml1结合位点上的MS结果,确定新发现的插入结构域的功能以及通过我们的结构确定的赋予底物特异性的关键残基的作用。最后,我们将研究由Fred Hutchninson癌症中心的Julian Simon博士发现的合成致命错配修复突变体的结构基础。这项工作将进一步加深我们对重要的核糖核苷酸还原酶是如何调节的理解,以及基于结构的抑制剂设计对增殖性疾病(如癌症)的治疗干预将是重要的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chris G Dealwis其他文献
Chris G Dealwis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chris G Dealwis', 18)}}的其他基金
Investigating the structural assembly of RNR multimers
研究 RNR 多聚体的结构组装
- 批准号:
8475488 - 财政年份:2012
- 资助金额:
$ 40.46万 - 项目类别:
Investigating the structural assembly of RNR multimers
研究 RNR 多聚体的结构组装
- 批准号:
8909392 - 财政年份:2012
- 资助金额:
$ 40.46万 - 项目类别:
Investigating the structural assembly of RNR multimers
研究 RNR 多聚体的结构组装
- 批准号:
8669995 - 财政年份:2012
- 资助金额:
$ 40.46万 - 项目类别:
Investigating the structural assembly of RNR multimers
研究 RNR 多聚体的结构组装
- 批准号:
8264407 - 财政年份:2012
- 资助金额:
$ 40.46万 - 项目类别:
CHARACTERIZATION OF NUCLEOTIDE DEPENDANT OLIOGOMERIC STATES OF RNR1P USING SAXS
使用 SAXS 表征 RNR1P 的核苷酸依赖性寡聚态
- 批准号:
8168654 - 财政年份:2010
- 资助金额:
$ 40.46万 - 项目类别:
DETERMINING ALLOSTERIC REGULATION OF RIBONUCLEOTIDE REDUCTASE
确定核糖核苷酸还原酶的变构调节
- 批准号:
8168655 - 财政年份:2010
- 资助金额:
$ 40.46万 - 项目类别:
STRUCTURAL STUDIES OF EUKARYOTIC RIBONUCLEOTIDE REDUCTASE
真核核糖核苷酸还原酶的结构研究
- 批准号:
8171985 - 财政年份:2010
- 资助金额:
$ 40.46万 - 项目类别:
STRUCTURAL STUDIES OF YEAST RIBONUCLEOTIDE REDUCTASE, AMYLOID-RECOGNIZING ANT
酵母核糖核苷酸还原酶、淀粉样蛋白识别蚂蚁的结构研究
- 批准号:
7956850 - 财政年份:2009
- 资助金额:
$ 40.46万 - 项目类别:
STRUCTURAL STUDIES OF YEAST RIBONUCLEOTIDE REDUCTASE, AMYLOID-RECOGNIZING ANT
酵母核糖核苷酸还原酶、淀粉样蛋白识别蚂蚁的结构研究
- 批准号:
7956842 - 财政年份:2009
- 资助金额:
$ 40.46万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 40.46万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 40.46万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 40.46万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 40.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 40.46万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 40.46万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 40.46万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 40.46万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 40.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 40.46万 - 项目类别: